Skip to content

Doxercalciferol

Vitamin D2 Analog — SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

Also known as: hectorol

OfpFDA approvedATC H05BX03

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Doxercalciferol is an ofp drug in the Vitamin D2 Analog class catalogued in DrugCentral. It was first approved by the FDA in 1999. DrugCentral lists 1 molecular target, including VDR. Recorded indications include Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis.

  • Approval status: ofp (first approved 1999 by the FDA).
  • Drug class: Vitamin D2 Analog.
  • Molecular targets: VDR (1 listed in DrugCentral).
  • Indications: Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis.
  • ATC code: H05BX03 (Other anti-parathyroid agents).
  • Molecular formula: C28H44O2; molecular weight 412.66 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis

Off-label uses (1)

  • Hyperparathyroidism Secondary to Chronic Renal Failure

Contraindications (5)

  • Disease of liver
  • Hypercalcemia
  • Hyperphosphatemia
  • Hypervitaminosis D
  • Hypoparathyroidism

Mechanism & targets

Established pharmacologic classVitamin D2 Analog

Molecular targets (1)

TargetGeneActionActivity
Vitamin D3 receptorVDRagonist—

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1999-06-09FDA—GENZYME CORP

ATC classification

ATC codeTherapeutic hierarchy
H05BX03SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS › CALCIUM HOMEOSTASIS › ANTI-PARATHYROID AGENTS › Other anti-parathyroid agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Drug hypersensitivity587.3
Pruritus105.1
Dyspnoea74.7
Blood parathyroid hormone abnormal71.1
Flushing56.2
Unresponsive to stimuli51.9
Feeling hot49.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Doxercalciferol is on its molecule page.

Molecular formulaC28H44O2
Molecular weight412.66 g/mol
CAS number54573-75-0
InChIKeyHKXBNHCUPKIYDM-CGMHZMFXSA-N
PubChem CID5281107
CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Doxercalciferol used for?

DrugCentral lists the following indications for Doxercalciferol: Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis.

How does Doxercalciferol work?

Its molecular targets in DrugCentral include VDR (agonist).

When was Doxercalciferol first approved?

Doxercalciferol was first approved by the FDA in 1999.

What drug class does Doxercalciferol belong to?

Doxercalciferol is in the Vitamin D2 Analog class.

What is the chemical formula of Doxercalciferol?

Doxercalciferol has the molecular formula C28H44O2 and a molecular weight of 412.66 g/mol.

Browse: all drugs starting with D · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval1999-06-09
AgencyFDA
Targets1
Indications1
FormulaC28H44O2
DrugCentral ID957
Interactive profile